西米普利单抗序贯索尼德吉治疗晚期皮肤鳞状细胞癌和基底细胞癌获完全缓解
一例78岁女性患者,左耳廓局部晚期基底细胞癌(BCC)及左耳前、颈部皮肤鳞状细胞癌(CSCC)伴腮腺及多发小淋巴结转移。多学科肿瘤委员会建议西米普利单抗(350 mg 静脉每3周)治疗13周期后,CSCC病灶组织学确认完全缓解,但BCC未变。改用索尼德吉(200 mg 口服每日)3个月后,BCC经3处钻孔活检确认完全缓解。两种药物耐受良好,仅西米普利单抗治疗前3周出现轻度乏力(CTC 1级),无实验室异常。
要点
- 西米普利单抗350 mg静脉每3周治疗13周期后,两处CSCC病灶组织学确认完全缓解。
- 索尼德吉200 mg口服每日治疗3个月后,BCC经3处钻孔活检确认完全缓解。
- 两药耐受良好,仅西米普利单抗前3周出现轻度乏力(CTC 1级),无实验室异常。
核心结论
- 西米普利单抗序贯索尼德吉治疗后,该患者CSCC和BCC病灶均获得完全缓解,且两药耐受良好。
研究设计与样本
- 病例报告:一例78岁女性患者,左耳廓局部晚期BCC(既往3次不完全切除)及左耳前、颈部两处快速生长的外生性CSCC病灶,CT显示腮腺受累及多发小淋巴结转移。
主要发现
- 西米普利单抗350 mg静脉每3周治疗13周期后,两处CSCC病灶组织学确认完全缓解,但左耳BCC未见变化且仍无症状。
- 索尼德吉200 mg口服每日治疗3个月后,BCC病灶明显消退,经3处钻孔活检确认完全缓解。
- 两药耐受良好,仅西米普利单抗治疗前3周出现轻度乏力(CTC 1级),无实验室异常。
临床怎么用
- 本研究中心的多学科肿瘤委员会建议对CSCC采用西米普利单抗全身治疗。
- 本研究中心的多学科肿瘤委员会认为该BCC不适合根治性切除或放疗,遂给予索尼德吉治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 78-year-old woman was referred to our skin cancer centre with three previous incomplete resections in the left cavum conchae of a deep-infiltrating locally advanced, but still asymptomatic basal cell carcinoma (BCC). The patient noted furthermore two rapidly growing exophytic lesions in the left preauricular and cervical area in the last weeks. The clinical and histological distinction of locally advanced from metastatic cutaneous squamous cell carcinoma (CSCC) lesions was challenging. Imaging analysis with CT scans showed, however, an involvement of the parotid gland as well as multiple small lymph node metastases. The interdisciplinary tumour board decision at our institution recommended a systemic treatment with the PD1-antibody cemiplimab. After 13 cycles with cemiplimab at a dose of 350 mg intravenously every 3-weeks, the patient showed a complete response of the two CSCC lesions with histological confirmation. However, the BCC of the left ear appeared to be unchanged and still asymptomatic. The interdisciplinary tumour board considered this tumour to be no candidate for a curative resection or irradiation. Therefore, the patient was exposed to the hedgehog inhibitor sonidegib with a conventional dose of 200 mg orally per day. After 3 months of treatment, the tumour showed a markable regression and a complete response was confirmed by 3-punch biopsies from this preoperated lesion. Both cemiplimab and sonidegib were excellently tolerated with almost no adverse events apart from a mild fatigue (CTC grade 1) over the first 3 weeks of the cemiplimab therapy. There were no laboratory abnormalities found.
引用
- Weis J, Grote C, Weichenthal M, et al. Complete response of advanced cutaneous squamous cell and basal cell carcinomas with sequential cemiplimab and sonidegib therapy. J Eur Acad Dermatol Venereol. 2022. PMID: 34855253. doi:10.1111/jdv.17403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。